Bimzelx® (bimekizumab-bkzx) from UCB is now under FDA review for a total of four potential new indications. Supplemental biologics license applications (sBLA) were submitted in February for three spondyloarthritides indications: psoriatic arthritis (PsA),...
As the rate of growth of nurse practitioners (NPs) and physician assistants (PAs) in the US continues to rise rapidly, research shows that the share of healthcare visits provided by NPs and PAs has increased by 11% since 2013. According to the latest data, NPs and PAs...
Galderma has submitted Biologics License Applications (BLAs) for nemolizumab for the treatment of prurigo nodularis (PN) and for moderate to severe atopic dermatitis (AD) in adolescents and adults. Nemolizumab is a first-in-class investigational monoclonal antibody...
Dermavant Sciences has submitted a Supplemental New Drug Application (sNDA) to the U.S. FDA for Vtama® (tapinarof) cream, 1% for the topical treatment of atopic dermatitis (AD) in adults and children 2 years of age and older. VTAMA cream, 1% is currently FDA-approved...
By Joe Gorelick, MSN, FNP-C Patients with vitiligo incur significantly higher healthcare costs than people without the skin condition, a new study published in Journal of Investigative Dermatology shows. In addition to direct costs that may be associated with managing...
By Joe Gorelick, MSN, FNP-C Individuality drives the definition of beauty for nearly three-quarters of Americans participating in a comprehensive survey by Allergan Aesthetics, an AbbVie. “Decoding the Future of Aesthetic Individuality” also reveals that...